129 related articles for article (PubMed ID: 35439537)
1. Blocking FSTL1 boosts NK immunity in treatment of osteosarcoma.
Ogiwara Y; Nakagawa M; Nakatani F; Uemura Y; Zhang R; Kudo-Saito C
Cancer Lett; 2022 Jul; 537():215690. PubMed ID: 35439537
[TBL] [Abstract][Full Text] [Related]
2. CD11b
Kudo-Saito C; Ogiwara Y; Imazeki H; Boku N; Uemura Y; Zhang R; Kawano-Nagatsuma A; Kojima M; Ochiai A
Am J Cancer Res; 2021; 11(11):5428-5439. PubMed ID: 34873470
[TBL] [Abstract][Full Text] [Related]
3. Sulforaphene inhibits the progression of osteosarcoma via regulating FSTL1/NF-κB pathway.
Zhang G; Jin C; Zhu Y; Fu F; Wang G; Li S
Life Sci; 2020 Dec; 263():118485. PubMed ID: 33017573
[TBL] [Abstract][Full Text] [Related]
4. Blocking the FSTL1-DIP2A Axis Improves Anti-tumor Immunity.
Kudo-Saito C; Ishida A; Shouya Y; Teramoto K; Igarashi T; Kon R; Saito K; Awada C; Ogiwara Y; Toyoura M
Cell Rep; 2018 Aug; 24(7):1790-1801. PubMed ID: 30110636
[TBL] [Abstract][Full Text] [Related]
5. FSTL1 Secreted by Activated Fibroblasts Promotes Hepatocellular Carcinoma Metastasis and Stemness.
Loh JJ; Li TW; Zhou L; Wong TL; Liu X; Ma VWS; Lo CM; Man K; Lee TK; Ning W; Tong M; Ma S
Cancer Res; 2021 Nov; 81(22):5692-5705. PubMed ID: 34551961
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of follistatin-like 1 mediates tumor immune evasion in nasopharyngeal carcinoma.
Zhou X; Xiao X; Huang T; Du C; Wang S; Mo Y; Ma N; Murata M; Li B; Wen W; Huang G; Zeng X; Zhang Z
Oncotarget; 2016 Mar; 7(13):16433-44. PubMed ID: 26918942
[TBL] [Abstract][Full Text] [Related]
7. FSTL1 suppresses tumor cell proliferation, invasion and survival in non-small cell lung cancer.
Ni X; Cao X; Wu Y; Wu J
Oncol Rep; 2018 Jan; 39(1):13-20. PubMed ID: 29115636
[TBL] [Abstract][Full Text] [Related]
8. Targeting FSTL1 prevents tumor bone metastasis and consequent immune dysfunction.
Kudo-Saito C; Fuwa T; Murakami K; Kawakami Y
Cancer Res; 2013 Oct; 73(20):6185-93. PubMed ID: 23966294
[TBL] [Abstract][Full Text] [Related]
9. Fstl1 Promotes Glioma Growth Through the BMP4/Smad1/5/8 Signaling Pathway.
Jin X; Nie E; Zhou X; Zeng A; Yu T; Zhi T; Jiang K; Wang Y; Zhang J; You Y
Cell Physiol Biochem; 2017; 44(4):1616-1628. PubMed ID: 29212066
[TBL] [Abstract][Full Text] [Related]
10. DIP2A functions as a FSTL1 receptor.
Ouchi N; Asaumi Y; Ohashi K; Higuchi A; Sono-Romanelli S; Oshima Y; Walsh K
J Biol Chem; 2010 Mar; 285(10):7127-34. PubMed ID: 20054002
[TBL] [Abstract][Full Text] [Related]
11. Follistatin-like 1 attenuates apoptosis via disco-interacting protein 2 homolog A/Akt pathway after middle cerebral artery occlusion in rats.
Liang X; Hu Q; Li B; McBride D; Bian H; Spagnoli P; Chen D; Tang J; Zhang JH
Stroke; 2014 Oct; 45(10):3048-3054. PubMed ID: 25139876
[TBL] [Abstract][Full Text] [Related]
12. FSTL1 contributes to tumor progression via attenuating apoptosis in a AKT/GSK-3β - dependent manner in hepatocellular carcinoma.
Yang W; Wu Y; Wang C; Liu Z; Xu M; Zheng X
Cancer Biomark; 2017 Jul; 20(1):75-85. PubMed ID: 28655132
[TBL] [Abstract][Full Text] [Related]
13. Mitotic cell death caused by follistatin-like 1 inhibition is associated with up-regulated Bim by inactivated Erk1/2 in human lung cancer cells.
Bae K; Park KE; Han J; Kim J; Kim K; Yoon KA
Oncotarget; 2016 Apr; 7(14):18076-84. PubMed ID: 26716515
[TBL] [Abstract][Full Text] [Related]
14. Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma.
Nie E; Miao F; Jin X; Wu W; Zhou X; Zeng A; Yu T; Zhi T; Shi Z; Wang Y; Zhang J; Liu N; You Y
Oncogene; 2019 Apr; 38(15):2706-2721. PubMed ID: 30542120
[TBL] [Abstract][Full Text] [Related]
15. Effects of FSTL1 on cell proliferation in breast cancer cell line MDA‑MB‑231 and its brain metastatic variant MDA‑MB‑231‑BR.
An J; Wang L; Zhao Y; Hao Q; Zhang Y; Zhang J; Yang C; Liu L; Wang W; Fang D; Lu T; Gao Y
Oncol Rep; 2017 Nov; 38(5):3001-3010. PubMed ID: 29048681
[TBL] [Abstract][Full Text] [Related]
16. FSTL1 Promotes Metastasis and Chemoresistance in Esophageal Squamous Cell Carcinoma through NFκB-BMP Signaling Cross-talk.
Lau MC; Ng KY; Wong TL; Tong M; Lee TK; Ming XY; Law S; Lee NP; Cheung AL; Qin YR; Chan KW; Ning W; Guan XY; Ma S
Cancer Res; 2017 Nov; 77(21):5886-5899. PubMed ID: 28883005
[TBL] [Abstract][Full Text] [Related]
17. FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation.
Cheng S; Huang Y; Lou C; He Y; Zhang Y; Zhang Q
Cancer Biol Ther; 2019; 20(3):328-337. PubMed ID: 30336071
[TBL] [Abstract][Full Text] [Related]
18. Endothelin-1 promotes osteosarcoma cell invasion and survival against cisplatin-induced apoptosis.
Zhao Y; Liao Q; Zhu Y; Long H
Clin Orthop Relat Res; 2011 Nov; 469(11):3190-9. PubMed ID: 21656314
[TBL] [Abstract][Full Text] [Related]
19. Follistatin-Like-1 (FSTL1) Is a Fibroblast-Derived Growth Factor That Contributes to Progression of Chronic Kidney Disease.
Maksimowski NA; Song X; Bae EH; Reich H; John R; Pei Y; Scholey JW; Nephrotic Syndrome Study Network Neptune
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502419
[TBL] [Abstract][Full Text] [Related]
20. Mediator of RNA polymerase II transcription subunit 19 promotes osteosarcoma growth and metastasis and associates with prognosis.
Yu W; Zhang Z; Min D; Yang Q; Du X; Tang L; Lin F; Sun Y; Zhao H; Zheng S; He A; Li H; Yao Y; Shen Z
Eur J Cancer; 2014 Apr; 50(6):1125-36. PubMed ID: 24565852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
